Pilot Phase II Trial of Imatinib Mesylate in Neurofibromatosis Type 1 patients with Plexiform Neurofibromas

BACKGROUND: Plexiform neurofibromas (PN) are slow growing chemoradiotherapy resistant tumours arising in patients with neurofibromatosis type I (NF1). Currently there are no viable therapeutic options for patients whose life-threatening plexiform neurofibromas cannot be surgically removed due to pro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Robertson, Kent A., Nalepa, Grzegorz, Yang, Feng-Chun, Bowers, Daniel C., Ho, Chang Y., Hutchins, Gary D., Croop, James M., Vik, Terry A., Denne, Scott C., Parada, Luis F., Hingtgen, Cynthia M., Walsh, Laurence E., Yu, Menggang, Pradhan, Kamnesh R., Edwards-Brown, Mary K., Cohen, Mervyn D., Fletcher, James W., Travers, Jeffrey B., Staser, Karl W., Lee, Melissa W., Sherman, Marcie R., Davis, Cynthia J., Miller, Lucy C., Ingram, David A., Clapp, D. Wade
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380388/
https://ncbi.nlm.nih.gov/pubmed/23099009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70414-X
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki